Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine how often people with sickle cell anemia develop pulmonary hypertension-a serious disease in which blood pressure in the artery to the lungs is elevated.
Men and women 18 years of age and older with sickle cell anemia may be eligible for this study. Participants will undergo an evaluation at Howard University's Comprehensive Sickle Cell Center in Washington, D.C. or at the National Institutes of Health in Bethesda, Maryland. It will include the following:
- medical history
- physical examination
- blood collection (no more than 50 ml., or about 1/3 cup) to confirm the diagnosis of sickle cell anemia, sickle cell trait or beta-thalassemia (Some blood will be stored for future research testing on sickle cell anemia.)
- echocardiogram (ultrasound test of the heart) to check the pumping action of the heart and the rate at which blood travels through the tricuspid valve.
Following this evaluation, a study nurse will contact participants twice a month for 2 months and then once every 3 months for the next 3 years for a telephone interview. The interview will include questions about general health and recent health-related events, such as hospitalizations or emergency room visits.
| Condition |
|---|
|
Pulmonary Hypertension Sickle Cell Anemia |
| Study Type: | Observational |
| Official Title: | Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients With Sickle Cell Anemia |
| Estimated Enrollment: | 1500 |
| Study Start Date: | February 2001 |
Sickle cell anemia is an autosomal recessive disorder and the most common genetic disease affecting African-Americans. Approximately 0.15% of African-Americans are homozygous for sickle cell disease, and 8% have sickle cell trait. Acute pain crisis, acute chest syndrome (ACS), and secondary pulmonary hypertension are common complications of sickle cell anemia. Mortality rates of sickle cell patients with pulmonary hypertension are significantly increased as compared to patients without pulmonary hypertension. Recent studies report up to 40% mortality at 22 months after detection of elevated pulmonary artery pressures in sickle cell patients. Furthermore, pulmonary hypertension is thought to occur in up to 30% of clinic patients with sickle cell anemia.
This study is designed to determine the prevalence and prognosis of secondary pulmonary hypertension in adult patients with sickle cell anemia, and to determine whether genetic polymorphisms in candidate genes contribute to its development or response to treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
- INCLUSION CRITERIA:
All volunteer subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study. Decisional impaired subjects will not be included in this study because it does not offer the prospect of direct benefit.
Sickle Cell Patients:
Male and females over 18 years of age.
Diagnosis of sickle cell disease (electrophoretic documentation of SS, SC, or S-beta thallassemia genotype is required).
EXCLUSION CRITERIA:
Sickle Cell Patients:
Hb A-only phenotype and sickle cell trait.
Decisionally impaired subjects.
INCLUSION CRITERIA:
Control Subjects:
Male and females African American subjects over 18 years of age.
Exclusion of sickle cell disease (electrophoretic documentation of hemoglobin A is required).
EXCLUSION CRITERIA:
Control Subjects:
Diagnosis of sickle cell disease (electrophoretic documentation of SS, or SC, or SB thallassemia genotype is required.
Decisionally impaired subjects.
Contacts and Locations| Contact: James Nichols, R.N. | (301) 435-2345 | jnichols@mail.nih.gov |
| Contact: James G Taylor, M.D. | (301) 435-7895 | jamesta@mail.nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 prpl@mail.cc.nih.gov | |
| Principal Investigator: | James G Taylor, M.D. | National Heart, Lung, and Blood Institute (NHLBI) |
More Information
Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00011648 History of Changes |
| Other Study ID Numbers: | 010088, 01-H-0088 |
| Study First Received: | February 24, 2001 |
| Last Updated: | December 19, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
Echocardiogram Morbidity Mortality Sickle Cell Anemia Secondary Pulmonary Hypertension |
Additional relevant MeSH terms:
|
Anemia Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Hypertension Hypertension, Pulmonary Hematologic Diseases |
Hemoglobinopathies Genetic Diseases, Inborn Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 23, 2013